NCT02361866

To Evaluate the Effectiveness(Immunogeneicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Adults

Randomized, Double Blind, Multicenter, Phase III Study to Evaluate the Effectiveness(Immunogeneicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Adults

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 376 (actual)
• Sponsor: Green Cross Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the effectiveness(immunogeneicity) and safety of 'GC1107' administered intramuscularly in healthy Adults.

Detailed description

Randomized, double blind, multicenter, phaseⅢ study

Conditions

• Bacterial Infections

Interventions

Type	Name	Description
BIOLOGICAL	GC1107	0.5 ml, Intramuscular, single dose(day0)
BIOLOGICAL	Tetanus and Diphtheria(Td vaccine)	0.5ml, Intramuscular, single dose(day0) only applicable step1

Timeline

• Start date: 2014-05-01
• Primary completion: 2014-09-01
• Completion: 2014-10-01
• First posted: 2015-02-12
• Last updated: 2015-02-12

Locations

1 site across 1 country: South Korea